Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
Make Hay While the Sun Shines. Up 6,400%.
Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have...
Initiating Coverage on Mitesco (MITI) FKA True Nature Holdings (TNTY) $0.02. Adding to Watch...
Click here to download.
Dalrada (DFCO) Appoints Gregory L. Remsen To Vice President of Strategic Relationships.
Dalrada Financial Corporation Appoints Gregory L. Remsen To Vice President of Strategic Relationships
DALRADA NEWS ARCHIVE
True Nature | Mitesco (MITI) Raising $15 Million.
LIVE CHART
Mitesco, Inc. Announces up to $15 Million Unit Preferred Capital...
Adding American BriVision (ABVC) $2.00 to Watch List.
New client and an incubator, studying now. Thinly, thinly traded. We like what we've read so far about their vitreous substitute (eyeball...
Smart for Life (SMFL) Featured by New to the Street
Interviews to Air on National Television Including Bloomberg and Fox Business
MIAMI, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Smart...
Dalrada (DFCO) Legal Counsel
WEBSITE
CONTINUOUSLY UPDATED
Dalrada Financial Adds Robbe to Board of DirectorsDalrada Financial Corporation Hires Fletcher...
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
